MediciNova Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.21
- Today's High:
- $2.27
- Open Price:
- $2.26
- 52W Low:
- $1.89
- 52W High:
- $2.73
- Prev. Close:
- $2.25
- Volume:
- 20555
Company Statistics
- Market Cap.:
- $110.35 million
- Book Value:
- 1.329
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $4.04 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -11.16%
- Return on Equity TTM:
- -17.55%
Company Profile
MediciNova Inc had its IPO on 2005-02-08 under the ticker symbol MNOV.
The company operates in the Healthcare sector and Biotechnology industry. MediciNova Inc has a staff strength of 13 employees.
Stock update
Shares of MediciNova Inc opened at $2.26 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.21 - $2.27, and closed at $2.24.
This is a -0.44% slip from the previous day's closing price.
A total volume of 20,555 shares were traded at the close of the day’s session.
In the last one week, shares of MediciNova Inc have slipped by -5.88%.
MediciNova Inc's Key Ratios
MediciNova Inc has a market cap of $110.35 million, indicating a price to book ratio of 1.6907 and a price to sales ratio of 2877.377.
In the last 12-months MediciNova Inc’s revenue was $0 with a gross profit of $4.04 million and an EBITDA of $-13374085. The EBITDA ratio measures MediciNova Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MediciNova Inc’s operating margin was 0% while its return on assets stood at -11.16% with a return of equity of -17.55%.
In Q2, MediciNova Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
MediciNova Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.94
Its diluted EPS in the last 12-months stands at $-0.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.94. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MediciNova Inc’s profitability.
MediciNova Inc stock is trading at a EV to sales ratio of 1142.7224 and a EV to EBITDA ratio of -5.2859. Its price to sales ratio in the trailing 12-months stood at 2877.377.
MediciNova Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $68.72 million
- Total Liabilities
- $2.82 million
- Operating Cash Flow
- $-18577.00
- Capital Expenditure
- $18577
- Dividend Payout Ratio
- 0%
MediciNova Inc ended 2024 with $68.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $68.72 million while shareholder equity stood at $65.18 million.
MediciNova Inc ended 2024 with $201792.00 in deferred long-term liabilities, $2.82 million in other current liabilities, 49046.00 in common stock, $-412919501.00 in retained earnings and $9.60 million in goodwill. Its cash balance stood at $52.88 million and cash and short-term investments were $52.88 million. The company’s total short-term debt was $201,277 while long-term debt stood at $0.
MediciNova Inc’s total current assets stands at $53.52 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $548221.00 and inventory worth $0.
In 2024, MediciNova Inc's operating cash flow was $-18577.00 while its capital expenditure stood at $18577.
Comparatively, MediciNova Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.24
- 52-Week High
- $2.73
- 52-Week Low
- $1.89
- Analyst Target Price
- $16
MediciNova Inc stock is currently trading at $2.24 per share. It touched a 52-week high of $2.73 and a 52-week low of $2.73. Analysts tracking the stock have a 12-month average target price of $16.
Its 50-day moving average was $2.38 and 200-day moving average was $2.29 The short ratio stood at 24.91 indicating a short percent outstanding of 0%.
Around 298.3% of the company’s stock are held by insiders while 2260% are held by institutions.
Frequently Asked Questions About MediciNova Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company’s product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.